Introduction Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive disease that results from the accumulation of transthyretin (TTR) fibrils in the extracellular space of the myocardium, leading to heart failure.1 The pathogenesis of ATTR-CA results from a reduction in cardiac compliance due to amyloid fibril deposition, but recent observations suggest that soluble TTR intermediate oligomers

Since 2019, coronavirus disease 2019 (COVID-19) has affected millions of individuals worldwide, leading to multiple deaths and numerous long-term multiorgan sequelae. In patients with COVID-19, cardiovascular diseases, including heart failure (HF), are common and associated with an increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections1 and high mortality rates.2

Click on the article title to read more.

Click on the article title to read more.

Both American and European heart failure (HF) guidelines currently recommend initiation and optimization of guideline-directed medical therapy (GDMT), which is composed of renin–angiotensin system (RAS) inhibitors, β-blocker, mineralocorticoid receptor antagonist (MRA), and sodium–glucose cotransporter 2 (SGLT2) inhibitor, during the hospitalization for acute HF (AHF).1-3 In previous clinical trials

Timely referrals for transplantation and left ventricular assist device (LVAD) play a key role in favourable outcomes in patients with advanced heart failure (HF). Cardiovascular mortality, driven by sudden cardiac death, is the main reason for dying while waiting for heart transplantation (HTx). The purpose of the Preventive Catheter Ablation for ventricular arrhythmiaS in patients with end-sTage

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Diuretics play a central role in the management of patients with heart failure. In fact, they are used to achieve and maintain euvolaemia through adequate fluid balance. The effects, clinical benefits and implications of diuretic therapy are well established. However, little is known about the inconveniences posed to patients by diuretics and the adaptations adopted by them to counteract these challenges

The table 1 in abstract “Length of hospital stay, re-hospitalization rates and comorbidities in patients with worsening heart failure. Data from 3 large cohort studies in the US, Germany and Japan” by A Alexander Michel, e. al. has been updated as follows. Characteristics Germany n = 47,003 US n = 75,140 Japan n = 9,091 Mean age (SD), years 78.91 (10.02) 74.24 (10.88) 77.55 (10.02) Female n (%) 23

Click on the article title to read more.

Click on the article title to read more.

AimsData from US have shown a reversal in the improvement of heart failure (HF)‐related mortality over the last ~10 years. It is unknown whether these trends generalize to European universal healthcare systems. We assessed temporal trends in (i) HF‐related mortality in the overall national population; and (ii) all‐cause mortality following an incident HF diagnosis, overall and stratified by ejection

Concerns exist that intravenous (IV) iron might increase the risk of infections. The IRONMAN trial provided an opportunity to investigate whether giving IV ferric derisomaltose (FDI) to patients with heart failure and iron deficiency alters the rate of hospitalization or death due to infections.

AimsClinical practice guidelines are commonly written by professional societies in high‐income countries (HIC) with limited anticipation of implementation obstacles in other environments. We used heart failure (HF) guidelines as a paradigm to examine this concern, by conducting a survey to understand clinicians' ability to implement HF guidelines and their perceptions of the current HF guideline applicability

Click on the article title to read more.

Click on the article title to read more.

Introduction We are at a crucial point in time for those with cardiovascular diseases such as heart failure (HF). An estimated 64.3 million people are living with HF worldwide.1 In developed countries, the prevalence of diagnosed HF is estimated at 1–2% of the adult population,2, 3 and with factors such as our expanding ageing population, figures are set to double by 2040 (Figure 1). Figure 1 Open

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

AimsResting heart rate (HR) is a strong risk marker in patients with heart failure (HF), but the clinical implications of visit‐to‐visit changes in HR (ΔHR) are less well established. We aimed to explore the association between ΔHR and subsequent outcomes in a pooled dataset of two well‐characterized cohorts of patients with HF across the full range of left ventricular ejection fraction (LVEF).Methods

Baudry and colleagues reported trends in durable mechanical circulatory support (MCS), primarily left ventricular assist devices (LVADs), across Europe from 2018 to 2023.1 They highlighted the underutilization of durable MCS, despite heart failure (HF) remaining a leading cause of mortality. Their hypotheses—improvements in medical therapies, referral delays to advanced HF units, the COVID-19 pandemic

Click on the article title to read more.

Click on the article title to read more.

AimsTo estimate the global burden of myocarditis in the general population from 1990 to 2021.Methods and resultsData on myocarditis were retrieved from the Global Burden of Disease Study 2021. Incidence, deaths, and disability‐adjusted life years (DALYs), along with their age‐standardized rates (ASRs) per 100 000 population, were used to measure the burden of myocarditis. Global, regional, and national

AimsCardiac amyloidosis (CA) is characterized by deposition of amyloid fibrils within the extracellular space, causing disarray of the myocardial structure and capillary architecture. This study aims to characterize the prevalence of microvascular obstruction (MVO) in patients with CA and to assess the association between MVO and prognosis.Methods and resultsThe study population comprised 800 patients

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

AimsPilot studies indicate that immunoadsorption with subsequent IgG substitution (IA/IgG) induces beneficial effects in patients with dilated cardiomyopathy (DCM) and heart failure. This placebo‐controlled study investigates whether IA/IgG treatment enhances left ventricular (LV) systolic function as compared to a control group receiving pseudo‐treatment.MethodsThis multicentre, randomized, double‐blind

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.